跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 133 条关于
“Ikaros (IKZF1)”
全部
133
临床试验
33
药物
42
机构
16
资讯
42
10个月前
Kangpu's Novel Cereblon Modulator Shows 50% Response Rate in Heavily Pre-treated Multiple Myeloma Patients
去年
Kangpu's Novel Molecular Glue Modulator KPG-818 Receives IND Approval in China for Multiple Myeloma Treatment
上个月
The Second Act of Thalidomide: From Teratogen to the Foundation of Targeted Protein Degradation
去年
Nurix Therapeutics Advances BTK Degrader NX-5948 and Reinitiates NX-2127 Trial
去年
Nurix Therapeutics' BTK Degrader NX-5948 Shows Promise in B-Cell Malignancies and Autoimmune Diseases
8个月前
C4 Therapeutics Advances Cemsidomide Through Phase 2 Development as Potential Best-in-Class Multiple Myeloma Treatment
去年
Dasatinib Plus CAR T-Cell Therapy Achieves 85% Complete Molecular Remission in Newly Diagnosed Ph+ ALL
2年前
Nurix Therapeutics Outlines 2024 Strategic Priorities with Focus on Cancer and Autoimmune Diseases
7个月前
FDA Accepts Bristol Myers Squibb's Iberdomide NDA for Multiple Myeloma, Testing New Regulatory Flexibility
去年
C4 Therapeutics Announces 2025 Milestones for Oncology-Focused Degrader Medicines
第 1 页,共 5 页
上一页
下一页